* Lexicon Pharmaceuticals Inc reported a quarterly adjusted loss of 18 cents per share for the quarter , higher than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of six analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -18 cents to -15 cents per share.
* Revenue rose 980.2% to $1.75 million from a year ago; analysts expected $2.93 million.
* Lexicon Pharmaceuticals Inc's reported EPS for the quarter was a loss of 18 cents.
* The company reported a quarterly loss of $64.81 million.
* Lexicon Pharmaceuticals Inc shares had fallen by 19.1% this quarter and lost 17.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 4.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is 5.00 This summary was machine generated from LSEG data November 12 at 11:26 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.16 -0.18 Missed
Jun. 30 2024 -0.19 -0.17 Beat
Mar. 31 2024 -0.20 -0.20 Met
Dec. 31 2023 -0.22 -0.20 Beat
Comments